TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

LAMIVUDINE
Approved 2018-05-15
Jump to: Indications Approvals Trials Competitors Safety Patents
1
Indication
--
Phase 3 Trials
7
Years on Market

Details

Status
None (Tentative Approval)
First Approved
2018-05-15
Routes
ORAL
Dosage Forms
TABLET

Companies

HETERO LABS LTD III Aurobindo Pharma
Active Ingredient: LAMIVUDINE , TENOFOVIR DISOPROXIL FUMARATE

LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE Approval History

Loading approval history...

What LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE Treats

1 FDA approvals

Originally approved for its first indication in 2018 .

  • Other (1)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE FDA Label Details

Pro

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: NDA207315 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.